Literature DB >> 21055744

Cell selection by selective matrix adhesion is not sufficiently efficient for complete malignant cell depletion from contaminated human testicular cell suspensions.

Mieke Geens1, Ellen Goossens, Herman Tournaye.   

Abstract

OBJECTIVE: To investigate whether a selective matrix adhesion-based protocol can enrich germ cells and deplete cancer cells from contaminated human testicular cell suspensions.
DESIGN: Artificially contaminated and control testicular cell suspensions were selectively cultured. After each experimental step, the presence of B cells was evaluated by fluorescence-activated cell sorting (FACS) and/or polymerase chain reaction (PCR).
SETTING: Academic medical center. PATIENT(S): Five vasectomy reversal patients willing to donate testicular tissue for research after informed consent. INTERVENTION(S): In vitro culture, magnetic-activated cell sorting (MACS), matrix adhesion, FACS, and PCR. MAIN OUTCOME MEASURE(S): FACS analysis for CD49f and human leukocyte antigen (HLA) class I expression; PCR analysis for a 120-bp fragment of the B-cell receptor. RESULT(S): With the use of a matrix adhesion-based protocol, CD49f(+) HLA class I(-) cells could be highly enriched, but HLA class I(+) CD49f(-) cells could still be detected. PCR proved that the cell suspensions contained malignant cells originating from the cell line used to contaminate them. CONCLUSION(S): Even though an efficient enrichment of germ cells was achieved, the resulting population was not pure. Malignant cells were detected in selected cell suspensions of all five patients, demonstrating that the efficacy of this protocol is insufficient for clinical application.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055744     DOI: 10.1016/j.fertnstert.2010.09.054

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Fertility Preservation and Restoration Options for Pre-Pubertal Male Cancer Patients: Current Approaches.

Authors:  Elena Eugeni; Iva Arato; Rachele Del Sordo; Angelo Sidoni; Andrea Garolla; Alberto Ferlin; Riccardo Calafiore; Stefano Brancorsini; Francesca Mancuso; Giovanni Luca
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

2.  Strategies for fertility preservation and restoration in the male.

Authors:  M Geens
Journal:  Facts Views Vis Obgyn       Date:  2011

3.  Spermatogonial stem cells: What does the future hold?

Authors:  H Tournaye; E Goossens
Journal:  Facts Views Vis Obgyn       Date:  2011

Review 4.  Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside.

Authors:  Hooman Sadri-Ardekani; Anthony Atala
Journal:  Stem Cell Res Ther       Date:  2014-05-28       Impact factor: 6.832

Review 5.  Oncofertility: Pharmacological Protection and Immature Testicular Tissue (ITT)-Based Strategies for Prepubertal and Adolescent Male Cancer Patients.

Authors:  Elissavet Ntemou; Chrysanthi Alexandri; Pascale Lybaert; Ellen Goossens; Isabelle Demeestere
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

Review 6.  Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation.

Authors:  J Onofre; Y Baert; K Faes; E Goossens
Journal:  Hum Reprod Update       Date:  2016-08-27       Impact factor: 15.610

Review 7.  Cryostorage of immature and mature human testis tissue to preserve spermatogonial stem cells (SSCs): a systematic review of current experiences toward clinical applications.

Authors:  Nima Pourhabibi Zarandi; Guillermo Galdon; Stanley Kogan; Anthony Atala; Hooman Sadri-Ardekani
Journal:  Stem Cells Cloning       Date:  2018-07-06

Review 8.  Approaches and Technologies in Male Fertility Preservation.

Authors:  Mahmoud Huleihel; Eitan Lunenfeld
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.